Search results

Filters
Close
ADDED DATE
Added date
AUTHOR Please select
TOPICS Please select
WATCH / LISTEN / READ TIME
HFA 23: DAPA MODA: Dapaglifozin & Cardiac Remodelling in Chronic HF
Author(s): Domingo Figal Added: 11 months ago
ESC-HFA 2023 — Prof Domingo Pascual Figal (Hospital Clinico Universitario Virgen de la Arrixaca, SP) discusses the DAPA MODA study (NCT04707352). The study aimed to assess the effects of dapagliflozin on cardiac remodeling parameters, particularly LA geometry and function, and biomarkers reflecting pathophysiological pathways. Findings from ESC Heart Failure 2023 revealed that dapagliflozin… View more

Heart Failure
Job title: MD Washington University School of Medicine, St Louis, MO, US
Dr Mann is the Lewin Chair and Professor of Medicine, Cell Biology and Physiology, at the Washington University School of Medicine, and Cardiologist-in-chief at Barnes Jewish Hospital in St Louis, Missouri, US. His research focus has been the molecular and cellular basis of heart failure, with particular emphasis on the role of innate immunity in disease progression and recovery of the failing… View more
Job title: Consultant Cardiologist
Dr Henry J Dargie is Consultant Cardiologist at Western Infirmary, Glasgow, and Director of the National Advanced Heart Failure Service, Glasgow (1980-2010) Research Achievements Metolozone in renal failure and heart failure Total Body Potassium in heart and renal failure Early work on role of SNS in hypertension Early RCT work on role of captopril in HF LVH and ventricular arrhythmias… View more
Iron Deficiency and Heart Failure
Author(s): Pieter Martens Added: 2 years ago

Standards & Guidelines

Heart Failure
T1 and T2 Mapping in Uremic Cardiomyopathy: An Update
Author(s): Luca Arcari , Giovanni Camastra , Federica Ciolina , et al Added: 2 years ago

Imaging & Diagnostics
HFA 23: Trientine-HCL for Treatment of HFrEF
Author(s): James L Januzzi , Harriette Van Spall Added: 10 months ago
ESC-HFA 2023 - Late-Breaker host, Dr Harriette Van Spall (McMaster University, CA) is joined by Dr James Januzzi (Massachusetts General Hospital, US) to discuss the findings of the TRACER-HF trial. Trientine-HCL is an oral chelation agent. Preclinical trials suggest that this promotes a reverse cardiac remodelling effect in HFrEF patients. 200 patients with New York Heart Association Class II or… View more

Heart Failure
ESC-HFA 2023: Late-Breaking Science Video Collection
Author(s): Jasper J Brugts , Ahmad Masri , Marianna Fontana , et al Added: 11 months ago
Get the most out of the new data from, Late-breaker host, Dr Harriette Van Spall and Dr James Januzzi wrap up of the most impactful trials and studies presented at Heart Failure 2023. Delve into in-depth and critical discussions with Dr Van Spall in our thought-provoking Late-breaker Discussion series. For concise and practical take-home messages for practice and cardiovascular research… View more

Standards & Guidelines

Heart Failure
Author(s): Katerina Fountoulaki , Nikolaos Dagres , Efstathios K Iliodromitis Added: 3 years ago
Heart failure (HF) is a feared endpoint for most cardiovascular diseases and is a major cause of morbidity and mortality. The worldwide prevalence of HF is between 2 and 3 % and rises sharply at around 75 years of age, so that the prevalence in 70- to 80-year-old people is between 10–20 %. With a 50 % 5-year survival rate, HF is predicted to be the leading cause of all morbidity by 2020.1,2… View more

Heart Failure
Effects of S/V Therapy on Exercise Capacity in Patients with HFrEF
Author(s): Cinzia Nugara , Francesco Giallauria , Giuseppe Vitale , et al Added: 11 months ago

Imaging & Diagnostics

Heart Failure
Suppression of Tumourigenicity 2 in Heart Failure With Preserved Ejection Fraction
Author(s): Veronika Zach , Felix Lucas Bähr , Frank Edelmann Added: 4 years ago
Heart failure (HF) is a chronic, progressive disease with steadily increasing incidence rates and high morbidity and mortality that represents a major challenge in healthcare worldwide.1–3 The disease is characterised by chronic exacerbations, recurrent hospitalisations and poor prognosis.1,2 Survival rates in HF patients are lower than in patients suffering from some malignant diseases,… View more

Heart Failure

Electrophysiology & Arrhythmia